287 related articles for article (PubMed ID: 37994744)
21. The prognostic implications from molecular testing of thyroid cancer.
Ozgursoy OB; Eisele DW; Tufano RP
Otolaryngol Clin North Am; 2014 Aug; 47(4):595-607. PubMed ID: 25041960
[TBL] [Abstract][Full Text] [Related]
22. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
Smith N; Nucera C
J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
[TBL] [Abstract][Full Text] [Related]
23. Unveiling the future of metabolic medicine: omics technologies driving personalized solutions for precision treatment of metabolic disorders.
Singh S; Sarma DK; Verma V; Nagpal R; Kumar M
Biochem Biophys Res Commun; 2023 Nov; 682():1-20. PubMed ID: 37788525
[TBL] [Abstract][Full Text] [Related]
24. Omics for the future in asthma.
Abdel-Aziz MI; Neerincx AH; Vijverberg SJ; Kraneveld AD; Maitland-van der Zee AH
Semin Immunopathol; 2020 Feb; 42(1):111-126. PubMed ID: 31942640
[TBL] [Abstract][Full Text] [Related]
25. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
[TBL] [Abstract][Full Text] [Related]
26. Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision.
Hsieh JJ; Le V; Cao D; Cheng EH; Creighton CJ
J Pathol; 2018 Apr; 244(5):525-537. PubMed ID: 29266437
[TBL] [Abstract][Full Text] [Related]
27. Annotation-Free Deep Learning-Based Prediction of Thyroid Molecular Cancer Biomarker BRAF (V600E) from Cytological Slides.
Wang CW; Muzakky H; Lee YC; Lin YJ; Chao TK
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768841
[TBL] [Abstract][Full Text] [Related]
28. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis.
Nikiforova MN; Nikiforov YE
Expert Rev Mol Diagn; 2008 Jan; 8(1):83-95. PubMed ID: 18088233
[TBL] [Abstract][Full Text] [Related]
29. Clinical Proteomics for Precision Medicine: The Bladder Cancer Case.
Latosinska A; Frantzi M; Vlahou A; Merseburger AS; Mischak H
Proteomics Clin Appl; 2018 Mar; 12(2):. PubMed ID: 28980455
[TBL] [Abstract][Full Text] [Related]
30. Omics Data and Their Integrative Analysis to Support Stratified Medicine in Neurodegenerative Diseases.
La Cognata V; Morello G; Cavallaro S
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34062930
[TBL] [Abstract][Full Text] [Related]
31. Advances in targeted therapy and biomarker research in thyroid cancer.
Guo M; Sun Y; Wei Y; Xu J; Zhang C
Front Endocrinol (Lausanne); 2024; 15():1372553. PubMed ID: 38501105
[TBL] [Abstract][Full Text] [Related]
32. Papillary Thyroid Cancer: Genetic Alterations and Molecular Biomarker Investigations.
Abdullah MI; Junit SM; Ng KL; Jayapalan JJ; Karikalan B; Hashim OH
Int J Med Sci; 2019; 16(3):450-460. PubMed ID: 30911279
[TBL] [Abstract][Full Text] [Related]
33. Identifying biomarkers for predicting successful embryo implantation: applying single to multi-OMICs to improve reproductive outcomes.
Hernández-Vargas P; Muñoz M; Domínguez F
Hum Reprod Update; 2020 Feb; 26(2):264-301. PubMed ID: 32096829
[TBL] [Abstract][Full Text] [Related]
34. Unveiling the potential of proteomic and genetic signatures for precision therapeutics in lung cancer management.
Srivastava S; Jayaswal N; Kumar S; Sharma PK; Behl T; Khalid A; Mohan S; Najmi A; Zoghebi K; Alhazmi HA
Cell Signal; 2024 Jan; 113():110932. PubMed ID: 37866667
[TBL] [Abstract][Full Text] [Related]
35. Omics sciences and precision medicine in kidney cancer.
Dhuli K; Micheletti C; Medori MC; Maltese PE; Tanzi B; Tezzele S; Mareso C; Generali D; Donofrio CA; Cominetti M; Fioravanti A; Riccio L; Beccari T; Ceccarini MR; Stuppia L; Gatta V; Cristoni S; Cecchin S; Marceddu G; Bertelli M
Clin Ter; 2023; 174(Suppl 2(6)):46-54. PubMed ID: 37994748
[TBL] [Abstract][Full Text] [Related]
36. BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (review).
Leonardi GC; Candido S; Carbone M; Raiti F; Colaianni V; Garozzo S; Cinà D; McCubrey JA; Libra M
Mol Med Rep; 2012 Oct; 6(4):687-94. PubMed ID: 22858857
[TBL] [Abstract][Full Text] [Related]
37. [Intracellular signaling mechanisms in thyroid cancer].
Mondragón-Terán P; López-Hernández LB; Gutiérrez-Salinas J; Suárez-Cuenca JA; Luna-Ceballos RI; Erazo Valle-Solís A
Cir Cir; 2016; 84(5):434-43. PubMed ID: 27423883
[TBL] [Abstract][Full Text] [Related]
38. DNA methylation alterations as therapeutic prospects in thyroid cancer.
Zhang K; Li C; Liu J; Tang X; Li Z
J Endocrinol Invest; 2019 Apr; 42(4):363-370. PubMed ID: 29992502
[TBL] [Abstract][Full Text] [Related]
39. Precision Medicine Approach in Prostate Cancer.
Assadi M; Jokar N; Ghasemi M; Nabipour I; Gholamrezanezhad A; Ahmadzadehfar H
Curr Pharm Des; 2020; 26(31):3783-3798. PubMed ID: 32067601
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
